Læknablaðið - 15.03.1990, Síða 45

LÆKNABLAÐIÐ
165
HEIMILDIR
1. Anitschkow NN. A history of experimentation on
arterial atherosclerosis in animals. In: Blumenthal HT
editor. Cowdry’s arteriosclerosis, 2nd ed. Springfield,
IL: Charles C. Thomas, Publisher, 1967, 21.
2. Barr DP, Russ EM, Eder HA. Protein-lipid
relationships in human plasma. II. In: atherosclerosis
and related conditions. Am J Med 1951; 11: 480-93.
3. Lipid Research Clinics Coronary Primary Prevention
Trial Results. I. Reduction in incidence of coronary
heart disease. JAMA 1984; 251: 351-64.
4. Tyroler HA. Review of lipid lowering clinical trials in
relation to observational studies. Circulation 1987; 76:
No3, 515-22.
5. Kirby TJ. Cataracts produced by triparanol (MER/29).
Trans Am Opthal Soc 1967; 65: 494-543.
6. Steinberg D, Avigan J, Feigelson EB. Effects of
triparanol (MER-29) on cholesterol biosynthesis and
blood sterol levels in man. J Clin Invest 1961; 40:
884-93.
7. Endo A, Tsujita Y, Kuroda M, Tanzawa K.
Competitive inhibition of 3 hydroxy-3 methylglutaryl
- coenzym A reductase by ML - 236 A and ML -
236, fungai metabolites having hypocholesterolemic
activity. FEBS Letter 1976; 72; 323-6.
8. Bilheimer DW, Grundy SM, Brown MS, Goldstein
JL. Mevinolin and colestipol stimulate receptor
mediated clearance of low density lipoprotein
from plasma in familial hypercholesterolaemia
heterozygotes. Proc Natl Acad Sci USA 1983; 80:
4124-8.
9. Sigurðsson G, Þorsteinsson Þ. Lóvastatín meðferð við
hækkun fituprótína í blóði. Læknablaðið 1988; 74:
353-8.
10. McGee D, Gordon T. The results of the Framingham
study applied to four other U.S. based epidemiologic
studies of cardiovascular disease. In: Kannel
WB, Gordon T eds. The Framingham study: an
epidemiologic investigation of cardiovascular disease.
NIH Publication No. 76-1083. Bethesda: U.S.
Govemment Printing Office, 1976.
11. Expert committee on Prevention of Coronary
Heart Disease: Prevention of coronary disease. In:
Technical Report Series 678. Geneve: World Health
Organization 1982.
12. Shepard J, Betterridge DJ, Durrington P, Laker
M, Lewis B, Mann J, Miller JP, Reckless JPD,
Thompson GR. Strategies for reducing coronary
heart disease and desirable limits for blood
lipid concentrations: guidelines of the British
Hyperlipidaemia Association. Br Med J 1987; 295:
1245-6.
13. Malloy MJ, Kane JP, Kunitake ST, Tun P.
Complementarity of colestipol, niacin and lovastatin
in treatment of severe familial hypercholesterolemia.
Ann Int Med 1987; 107: 616-23.
14. Knekt P, Reunanen A, Aromaa A, Heliövaara M,
Hakulinen T, Hakama M. Semm cholesterol and risk
of cancer in a cohort of 39.000 men and women. J
Clin Epidemiol 1988; 41: 519-30.
15. Kranhaut D, Bosschieter EB, Drijver M, Coulander
CdL. Semm cholesterol and 25-year incidence of and
mortality from myocardial infarction and cancer. The
Zutphen study. Arch Intem Med 1988; 148: 1051-5.
16. Report of the National Cholesterol Education
Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults. Arch
Intem Med 1988; 148: 36-69.
17. Gordon T, Castelli WP, Hjortland MC, Kannel
WB, Dawber TR. High density lipoprotein as a
protective factor against coronary heart disease. The
Framingham study. Am J Med 1977; 62: 707-14.
18. Castelli WP, Garrison RJ, Wilson PWT, Abbott
RD, Kaloushi S, Kannel WB. Incidence of coronary
heart disease and lipoprotein cholesterol levels. The
Framingham study. JAMA 1986; 256: 2835-8.
19. Valeri A, Gelfand J. Blum C. Appel GB. Treatment
of the hyperlipidemia of the nephrotic syndrome: A
controlled trial. Am J Kidney Dis 1986; 8 (6); 388-
96.
20. Vega GL, Grundy SM. Lovastatin therapy in
nephrotic hyperlipidemia. Effects on lipoprotein
metabolism. Kidney Intemational 1988; 33: 1160-8.
21. Editorial. 3-Hydroxy-3-methylglutaryl Coenzyme A
(HMG-CoA) reductase inhibitors: A new class of
cholesterol-lowering agents. Ann Intem Med 1987;
107: 759-61.
22. Malenka DJ, Baron JA. Cholesterol and coronarý
heart disease. The importance of patient-specific
attributable risk. Arch Intem Med 1988; 148: 2247-
52.